Biological E. Limited – FDA 483, Nov 12, 2024

The FDA issued a Form 483 to Biological E. Limited, a sterile drug manufacturer in Medchal, Telangana, India, following an inspection from November 4 to November 12, 2024. The observations cite significant deviations from current Good Manufacturing Practices for sterile drug production.

The primary issues included a failure to follow procedures designed to prevent microbiological contamination. Investigators observed operators in aseptic areas with exposed skin due to improper gowning, direct handling of sterile products with gloved hands instead of specified tools, and actions like reaching over open vials. Furthermore, the firm's Quality Assurance failed to document these gowning deficiencies during video reviews, and glove integrity testing procedures were not correctly executed.

The second major concern involved inadequate aseptic process validation. Smoke studies, crucial for visualizing airflow, lacked a validated smoke source and did not accurately represent routine production activities. Interventions during these studies, such as operator movements and equipment manipulation, were either poorly filmed, showed unaddressed turbulence, or were entirely unsymmetrical to actual operations, failing to demonstrate proper airflow and potential contamination risks.

Biological E. Limited is required to implement comprehensive corrective and preventative actions to address these observations, ensuring the sterility and quality of its drug products.